Human α synuclein expressing transgenic mice
View Patent ↗In methods for screening treatments for, and treatment of, neurodegenerative diseases, aggregation in neurons of NACP/α-synuclein is measured and expression of a non-amyloidogenic protein is stimulated in order to reduce the level aggregration. For purposes of screening agents for treatment of neurodegenerative disease, oxidative stress in the neuronal cells is stimulated by introducing a mixture of metal-ions and hydrogen peroxide. Examples of appropriate metals include iron, aluminum, and copper. After introduction of the agent under evaluation for stimulation of expression of non-amyloidogenic protein, the effectiveness is measured by testing for a decrease in the level of aggregation of NACP/α-synuclein. In an exemplary embodiment, the non-amyloidogenic protein is β-synuclein. The aggregation of NACP/α-synuclein is dependent upon the concentration of metal ions in the neuronal cells. In addition, the presence of chelating agents appears to modulate the build-up of NACP/α-synuclein aggregates which are responsible for synaptic and neuronal dysfunction.
1. A transgenic mouse comprising a heterologous nucleic acid comprising a human α-synuclein-140 coding sequence,
wherein the heterologous nucleic acid is operatively linked to a PDGFβ promoter and is integrated into the genome of the transgenic mouse,
wherein the mouse expresses human α-synuclein-140 and exhibits intraneuronal inclusions, abnormal accumulation of NACP/α-synuclein accompanied by loss of presynaptic terminals in the neocotex, loss of neurofilament expressing a neurons in the neocortex and hippocampus, and increased ubiquitin immunoreactivity in comparison to non-transgenic control littermates.
2. The transgenic mouse of claim 1 , wherein the promoter comprises is a human PDGFβ promoter.
3. The transgenic mouse of claim 1 , wherein the heterologous nucleic acid further comprises an intron.
4. The transgenic mouse of claim 3 , wherein the intron comprises a viral intron sequence.
5. The transgenic mouse of claim 4 , wherein the viral intron sequence comprises an SV40 intron.
6. The transgenic mouse of claim 1 , wherein the heterologous nucleic acid comprising the α-synuclein-140 coding sequence is a cDNA sequence.
7. The transgenic mouse of claim 1 , wherein the heterologous nucleic acid further comprises a poly A sequence.
8. The transgenic mouse of claim 7 , wherein the poly A sequence comprises an SV40 poly A sequence.
9. The transgenic mouse of claim 1 , wherein the transgenic animal is heterozygous for the heterologous nucleic acid.
10. The transgenic mouse of claim 1 , wherein the transgenic animal is homozygous for the heterologous nucleic acid.
11. The transgenic mouse of claim 1 , wherein the human α-synuclein-140 coding sequence encodes a polypeptide comprising a sequence of SEQ ID NO:10.
12. The transgenic mouse of claim 1 , wherein the heterologous nucleic acid comprises human wild-type α-synuclein-140 cDNA, operably linked to a human PDFGβ promoter, an SV40 intron and an SV40 poly A.
13. A transgenic mouse line generated from the transgenic mouse of claim 10 ,
wherein mice of the transgenic mouse line express a human α-synuclein-140 and exhibit intraneuronal inclusions, abnormal accumulation of NACP/α-synuclein accompanied by loss of presynaptic terminals in the neocortex, loss of neurofilament expressing neurons in the neocortex and hippocampus, and increased ubiquitin immunoreactivity in comparison to non-transgenic control littermates.
14. A transgenic mouse cell line isolated from a transgenic mouse line of claim 13 , wherein the transgenic mouse cell line comprises a genome-integrated human α-synuclein-140 sequence operably linked to a PDGF β promoter and expresses α-synuclein-140 protein.